Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Preferred Stock Liabilities (2020 - 2023)

Mimedx (MDXG) has disclosed Preferred Stock Liabilities for 4 consecutive years, with $92.5 million as the latest value for Q3 2023.

  • Quarterly Preferred Stock Liabilities changed 0.0% to $92.5 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $92.5 million through Sep 2023, changed 0.0% year-over-year, with the annual reading at $92.5 million for FY2022, 0.0% changed from the prior year.
  • Preferred Stock Liabilities hit $92.5 million in Q3 2023 for Mimedx, roughly flat from $92.5 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $92.5 million in Q2 2021 to a low of $91.1 million in Q3 2020.
  • Historically, Preferred Stock Liabilities has averaged $92.3 million across 4 years, with a median of $92.5 million in 2021.
  • Biggest five-year swings in Preferred Stock Liabilities: increased 1.52% in 2021 and later changed 0.0% in 2022.
  • Year by year, Preferred Stock Liabilities stood at $91.6 million in 2020, then increased by 1.01% to $92.5 million in 2021, then changed by 0.0% to $92.5 million in 2022, then changed by 0.0% to $92.5 million in 2023.
  • Business Quant data shows Preferred Stock Liabilities for MDXG at $92.5 million in Q3 2023, $92.5 million in Q2 2023, and $92.5 million in Q1 2023.